<DOC>
	<DOCNO>NCT01055951</DOCNO>
	<brief_summary>The purpose study assess safety usability Solo™ insulin MicroPump subject type 1 diabetes pump user .</brief_summary>
	<brief_title>Feasibility Study Solo™ Insulin Pump</brief_title>
	<detailed_description>This multi center , one arm , open label prospective study ass safety usability Solo™ MicroPump Insulin Delivery System . The study include 30 day treatment period Solo MicroPump special care require maintain glycemic control optional extension period six month . The study consist 5 visit one follow phone call one week termination study . In case participate extension period , additional visit consist month . Visit 1 include eligibility , baseline evaluation training handle Solo™ System . If additional practice require patient enrol . Visit 2 commence Solo pump fill insulin . If additional practice require subject send home additional training period day practice use saline return visit 2 . Treatment visit take place 3 , 14 30 day enrolment . Additional visit take place 60 , 90 180 day depend extension period . Subjects ask record blood glucose measurement , daily activity carbohydrate consumption visit . Seven day termination study treatment telephone contact study subject take place purpose adverse event report completion DTSQ questionnaire . Measurements use assess safety device glucose level occurrence AE 's . Subjects complete DTSQ Performance questionnaires end treatment period usability evaluation . Blood urine test take visit 1 5 , vital sign physical examination evaluate study visit .</detailed_description>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age range : 18 60 year Israel 16 60 year Austria Type I diabetes pump treatment duration 6 month . Subjects use Humalog® , NovoRapid® , Apidra® 100U/ml insulin Measures glucose least four time per day . No one severe hypoglycemic ketoacidosis episode within one year Willing sign inform consent . Cooperative , willing attend study visit . A1c &gt; = 10.0 % Two documented event severe hypoglycemia within previous 12 month Diabetes relate hospitalization past 12 month Current significant diabetesrelated complication Pregnant , lactate plan become pregnant course study Substance alcohol abuse Uncontrolled hypertension Known dermal hypersensitivity medical adhesive Recurrent episode skin infection dermatological allergy Serious unstable medical psychological condition Current participation clinical study . Working competitor company</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Insulin pump</keyword>
	<keyword>Diabetes</keyword>
</DOC>